

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

State the full name of your company and the address of its principal office in Canada:

Pivot Pharmaceuticals Inc. (the "Company")
1275 West 6th Avenue
Vancouver, British Columbia V6H 1A6

Item 2. Date of Material Change

April 7, 2015

Item 3. News Release

The Company did not disseminate a news release. The Company announced the material change by filing a Form 8-K with the Securities and Exchange Commission.

Item 4. Summary of Material Change

The Company announced that it has changed its name from Neurokine Pharmaceuticals to Pivot Pharmaceuticals and has effected a 10 old for 1 new reverse stock split of its issued and outstanding common shares.

The reverse stock split was approved by shareholders of the Company at a special meeting held on September 26, 2014.

Full Description of Material Change

See attached Form 8-K attached hereto as Exhibit "A".

Item 5. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

If this report is being filed on a confidential basis in reliance of subsection 7.1(2) or (3) of National Instrument 51-102, state the reasons for such reliance.

Not Applicable.

Item 6. Omitted Information

Not Applicable.

Item 7. Executive Officer

Give the name and business telephone number of an executive officer of your company who is knowledgeable about the material change and the Report, or the name of an officer through whom such executive officer may be contacted.

Please contact BJ Bormann, President of the Company, at (604) 805-7783

Item 8. Date of Report

DATED April 17, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 7, 2015

PIVOT PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

British Columbia

333-161157

n/a

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1275 West 6th Avenue, Vancouver, British Columbia, Canada

V6H 1A6

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (604) 805-7783

NEUROKINE PHARMACEUTICALS INC.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.03 Amendments to Articles of Incorporation or Bylaws
Item 8.01 Other Items

On March 26, 2015, our board of directors, in accordance with the Articles of our company, approved a change of name of our company to Pivot Pharmaceuticals Inc.

Also on March 26, 2015, our company's board of directors approved a resolution to effect a reverse stock split of our issued and outstanding common shares on a ten (10) old for one (1) new basis. Upon effect of the reverse split, our issued and outstanding common shares will decrease from 1,058,637,668 common shares to approximately 105,863,767 common shares, without par value. The reverse stock split was approved by our shareholders at a special meeting held on September 26, 2014.

A Notice of Alteration to effect the change of name was filed and became effective with the British Columbia Registrar of Companies on April 7, 2015. No filing was required for the reverse stock split.

The name change and reverse split has been reviewed by the Financial Industry Regulatory Authority (FINRA) and has been approved for filing with an effective date of April 20, 2015.

The name change and reverse stock split will become effective with the OTC Bulletin Board at the opening of trading on April 20, 2015 under the symbol "NEUKD". The "D" will be placed on our ticker symbol for 20 business days at which time our symbol will change to "PVOTF". Our new CUSIP number is 72580T202.

Item 9.01 Financial Statements and Exhibits

3.1 Form 11, Notice of Alteration filed with the British Columbia Registrar of Companies with an effective date of April 7, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIVOT PHARMACEUTICALS INC.

/s/ BJ Bormann

BJ Bormann
President and Director

Date: April 17, 2015



**BC Registry
Services**

Mailing Address:
PO Box 9431 Stn Prov Govt
Victoria BC V8W 9V3
www.corporateonline.gov.bc.ca

Location:
2nd Floor - 940 Blanshard Street
Victoria BC
1 877 526-1526

Notice of Alteration

*FORM 11
BUSINESS CORPORATIONS ACT
Section 257*

Filed Date and Time: **April 7, 2015 10:23 AM Pacific Time**

Alteration Date and Time: **Notice of Articles Altered on April 7, 2015 10:23 AM Pacific Time**

NOTICE OF ALTERATION

Incorporation Number:

BC0649186

Name of Company:

NEUROKINE PHARMACEUTICALS INC.

Name Reservation Number:

NR1849764

Name Reserved:

PIVOT PHARMACEUTICALS INC.

ALTERATION EFFECTIVE DATE:

The alteration is to take effect at the time that this application is filed with the Registrar.

CHANGE OF NAME OF COMPANY

From:

NEUROKINE PHARMACEUTICALS INC.

To:

PIVOT PHARMACEUTICALS INC.